In a phase II study in patients with advanced ovarian or breast cancer associated with a germline BRCA1/2 mutation, continuous dosing of single-agent oral rucaparib led to a higher rate of response than intermittent intravenous (i.v.)dosing (response rate, 18% vs 2%) (Drew et al, 2016). Here, BRCA1 is linked to breast cancer.